Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Assets (2016 - 2026)

Ironwood Pharmaceuticals' Current Assets history spans 16 years, with the latest figure at $274.2 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 50.34% to $274.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $274.2 million, a 50.34% increase, with the full-year FY2025 number at $274.2 million, up 50.34% from a year prior.
  • Current Assets hit $274.2 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $273.8 million in the prior quarter.
  • Over the last five years, Current Assets for IRWD hit a ceiling of $866.4 million in Q1 2023 and a floor of $160.6 million in Q1 2025.
  • Historically, Current Assets has averaged $436.3 million across 5 years, with a median of $295.9 million in 2023.
  • Biggest five-year swings in Current Assets: skyrocketed 65.73% in 2021 and later tumbled 75.97% in 2024.
  • Tracing IRWD's Current Assets over 5 years: stood at $745.2 million in 2021, then grew by 4.75% to $780.6 million in 2022, then crashed by 70.12% to $233.3 million in 2023, then decreased by 21.83% to $182.4 million in 2024, then surged by 50.34% to $274.2 million in 2025.
  • Business Quant data shows Current Assets for IRWD at $274.2 million in Q4 2025, $273.8 million in Q3 2025, and $191.8 million in Q2 2025.